

Psoriatic eruption following immunotherapy with pembrolizumab: a case report

INTRODUCTION

PD-1 inhibitor-induced psoriasis, associated with immunotherapeutics used to fight cancer, is an uncommon and challenging adverse event, especially when severe and in patients without a dermatological history.

Tânia R. M. de Oliveira-Fernandes et al.

CASE REPORT

67-year-old man, phototype 2, agronomist, diabetic, receiving pembrolizumab for the treatment of renal cancer, who after the fifth dose developed progressive pruritic skin lesions characterized by disseminated erythematous-scaling plaques and papules.

PASI of 36

Biopsies: chronic psoriasiform dermatitis with eosinophilia.



DOI: 10.24875/PJDV.26000038